不同构成人参皂苷制备的理论模拟与实验研究

目的:构造成份比例不尽相同的人参皂苷提取物,为药理药效实验提供多种类型的试样.方法:采用UNIFAC基团贡献法进行液液萃取模拟,选择合适的萃取剂体系进行实验,并通过HPLC检测不同萃取剂体系下的人参皂苷.结果:随着萃取剂体系的变化,几种主要皂苷的含量发生相对变化,可构造出一系列具明显特征的人参皂苷提取物;在含量较高的几种皂苷中,-Rb1较易和-Re分离,而与-Rd较难分离,实验与理论预测的结果一致.结论:理论计算结合萃取剂体系的优化可构造有明显差异的人参皂苷提取物.     

大鼠肠管外翻模型对人参皂苷Rg1吸收机制的研究

目的 :建立准确、灵敏、可靠的Rg1HPLC MS测定方法 ,研究Rg1是否存在分肠段吸收的差异并考察小肠上皮组织上的P 糖蛋白 (P glycoprotein)对人参皂苷Rg1吸收的影响。方法 :在不同肠段 (回肠和空肠 )的肠管外翻模型中加入 2 0 μg·ml-1Rg1Krebs液 ,在不同时间点取样并测定囊内药物浓度 ,比较两个小肠段对Rg1通透能力的差异 ,同时观察P 糖蛋白抑制剂维拉帕米对Rg1吸收的影响。结果 :不同肠段 (回肠和空肠 )的体外模型试验结果表明 ,Rg1在不同肠段的吸收良好 ,且无明显差异。维拉帕米对Rg1的吸收未见显著影响。结论 :Rg1在大鼠的各个肠段的吸收无显著性差异 ,Rg1可能不是P 糖蛋白的底物。     

人参皂苷C-K静脉乳剂的制备及理化性质考察

目的研究人参皂苷C K静脉乳剂的处方及制备工艺 ,并对其理化性质进行考察。方法以人参皂苷C K为原料 ,以精制豆磷脂为乳化剂 ,加入适量的辅助乳化剂、稳定剂 ,用正交实验法优化乳剂的处方及工艺 ;用加速实验法考察乳剂的理化性质。结果制备的乳剂符合《中华人民共和国药典》对静脉乳剂的要求 ,经过影响因素试验确定了乳剂的储存条件。结论制备的乳剂性质稳定 ,为乳剂的进一步开发奠定了基础     

HPLC法测定三七药材中3种皂苷的含量

目的采用高效液相色谱法同时测定三七中三七皂苷R1、人参皂苷Rg1、人参皂苷Rb1的含量.方法采用luna C18(2)分析柱;以(A)乙腈-(B)0.05%磷酸二元线性梯度洗脱:0～8 min(20%A∶80%B),8～20 min(20%A～40%A)∶(80%B～60%B),20～30 min(40%A～20%A)∶(60%B～80%B),检测波长203 nm.结果测得三七皂苷R1、人参皂苷Rg1、人参皂苷Rb1的回收率分别是(97.7±1.6)%、(98.6±1.1)%、(99.2±0.8)%.线性范围分别是:三七皂苷R112～150 μg·mL-1(r=0.9990)、人参皂苷Rg140～500 μg·mL-1(r=0.999 4)、人参皂苷Rb144～550 μg·mL-1(r=0.999 7).结论采用高效液相色谱梯度洗脱法能将多种皂苷很好地分离检测,方法准确可靠,重复性好,结果稳定.     

Rg3对甲状腺癌血管生成抑制作用的临床观察

为了探讨人参皂甙Rg3对人甲状腺癌血管生成的抑制作用 ,对 18例甲状腺癌患者在术前 2周口服Rg3 ,观察手术切除癌内微血管密度 (microvesseldexsity ,MVD)的变化。结果实验组血管减少明显 ,高倍镜下可见血管内皮细胞支架塌陷、变性、坏死 ;而对照组血管无明显改变。实验组MVD值计数 10 8 69± 2 5 2 4,对照组MVD计数 160 5 2±47 45 ,两组比较差异有统计学意义 ,P <0 0 0 1。初步研究结果提示 ,Rg3具有抑制甲状腺癌血管生成的作用 ,可有效抑制其生长和转移。     

A Natural Compound (Ginsenoside Re) Isolated from <Emphasis Type="Italic">Panax ginseng</Emphasis> as a Novel Angiogenic Agent for Tissue Regeneration

No HeadingPurpose. The primary challenge for tissue engineering is to develop a vascular supply that can support the metabolic needs of the engineered tissues in an extracellular matrix. In this study, the feasibility of using a natural compound, ginsenoside Re, isolated from Panax ginseng in stimulating angiogenesis and for tissue regeneration was evaluated.Methods. Effects of ginsenoside Re on the proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs) were examined in vitro. Additionally, angiogenesis and tissue regeneration in a genipin-fixed porous acellular bovine pericardium (extracellular matrix; ECM) incorporated with ginsenoside Re implanted subcutaneously in a rat model were investigated. Basic fibroblast growth factor (bFGF) was used as a control.Results. It was found that HUVEC proliferation, migration in a Transwell plate, and tube formation on Matrigel were all significantly enhanced in the presence of bFGF or ginsenoside Re. Additionally, effects of ginsenoside Re on HUVEC proliferation, migration, and tube formation were dose-dependent and reached a maximal level at a concentration of about 30 g/ml. The in vivo results obtained at 1 week postoperatively showed that the density of neocapillaries and the tissue hemoglobin content in the ECMs were significantly enhanced by bFGF or ginsenoside Re. These results indicated that angiogenesis in the ECMs was significantly enhanced by loading with bFGF or ginsenoside Re. At 1 month postoperatively, vascularzied neo-connective-tissue fibrils were found to fill the pores in the ECMs loaded with bFGF or ginsenoside Re.Conclusions. The aforementioned results indicated that like bFGF, ginsenoside Re-associated induction of angiogenesis enhanced tissue regeneration, supporting the concept of therapeutic angiogenesis in tissue-engineering strategies.     

Isolation of ginsenoside Rb1 from Kalopanax pictus by eastern blotting using anti-ginsenoside Rb1 monoclonal antibody

Araliaceous species containing ginsenosides, the major active component in Panax species, were surveyed using ELISA and eastern blotting with anti-ginsenoside Rb1 monoclonal antibody. Immunoassay-guided fractionation of the methanol-soluble extracts of Araliaceous species led to the isolation of a known compound in the bark of Kalopanax pictus Nakai. The known compound was identified as ginsenoside Rb1 by spectroscopic methods and by comparison with an authentic sample. The result provided evidence that a combination of two immunoassays using monoclonal antibodies against ginsenosides is a powerful means of surveying new ginsenoside resources.     

趁鲜与传统切制人参饮片标准汤剂量值传递规律分析

目的 通过对人参趁鲜切制与传统切制饮片标准汤剂的量值传递规律进行分析,为人参趁鲜切制饮片的质量控制及应用开发研究提供参考。方法 经标准工艺分别制备10批具代表性的人参趁鲜与传统切制饮片及其标准汤剂,采用Agilent EC-C₁₈色谱柱（4.6 mm×150 mm,2.7 μm）,以乙腈（A）-0.1%磷酸水溶液（B）为流动相进行梯度洗脱（0~23 min,18%~21% A;23~35 min,21%~28% A;35~80 min,28%~32% A）,检测波长203 nm,建立标准汤剂的指纹图谱,并进行相似度评价、主成分分析（PCA）及偏最小二乘法-判别分析（PLS-DA）,以变量重要性投影（VIP）值>1筛选差异成分,对筛选出的已知差异成分进行定量分析,结合出膏率、转移率等指标,探讨人参趁鲜切制与传统切制饮片标准汤剂的量值传递规律差异。结果 人参趁鲜切制饮片与传统切制饮片标准汤剂指纹图谱相似度均>0.950,分别确定了18个共有峰,指认了其中9个共有峰;PCA及PLS-DA结果表明,2种饮片标准汤剂中指标成分的含量存在一定差异,人参趁鲜切制饮片中人参皂苷Rg₁、Re、Ro含量高于传统切制饮片,而人参皂苷Rb₁、Rc、Rb₂、Rd含量低于传统切制饮片,人参趁鲜切制饮片标准汤剂中人参皂苷Rg₁、Re、Rb₁、Ro含量高于传统切制饮片标准汤剂,而人参皂苷Rc、Rb₂、Rd在2种饮片标准汤剂中的含量相当。人参趁鲜切制饮片标准汤剂中人参皂苷Rg₁、Rb₁、Rc、Rb₂平均转移率均明显高于传统切制饮片标准汤剂（P<0.05）;人参皂苷Re、Rd平均转移率有所升高,但差异无统计学意义;人参皂苷Ro平均转移率差异无统计学意义,趁鲜切制饮片标准汤剂的出膏率明显高于传统切制饮片标准汤剂（P<0.05）。结论 趁鲜切制饮片标准汤剂的出膏率、指标成分含量及转移率均优于传统切制饮片标准汤剂,可为趁鲜切制饮片后续临床应用提供数据支持。     

人参皂苷Rg1对大鼠非酒精性脂肪性肝病和肠道菌群影响的研究

目的：探讨人参皂苷Rg1对大鼠非酒精性脂肪性肝病（non-alcoholic fatty liver disease,NAFLD）的改善情况及对肠道菌群的潜在影响。方法：将24只大鼠随机分为对照组、高脂高糖（high-fat and high-sugar,HFHS）组、人参皂苷Rg1低剂量治疗组、人参皂苷Rg1高剂量治疗组。采用HFHS饮食喂养制备大鼠NAFLD模型,给予人参皂苷Rg1灌胃干预治疗4周。麻醉处死大鼠,测量各组大鼠的体质量和肝重,计算肝重/体质量的比值;采用酶联免疫吸附实验（enzyme-linked immunosorbent assay,ELISA）分别检测各组大鼠血清总胆固醇（total cholesterol,TC）、甘油三酯（triglyceride,TG）、丙氨酸转氨酶（alanine aminotransferase,ALT）、天冬氨酸转氨酶（aspartate aminotransferase,AST）、低密度脂蛋白胆固醇（low density lipoprotein cholesterol,LDLC）、高密度脂蛋白胆固醇（high density li...